Hikma has announced the establishment of a Spanish subsidiary, marking the firm’s latest push into a new market alongside recent expansions in France and Canada. The moves are in line with a strategy laid out to Generics Bulletin several years ago by current CEO Riad Mishlawi.
Hikma has delivered on years-long plans by entering Spain’s generic injectables market, strengthening its European presence with the establishment of a Spanish subsidiary, Hikma España.
Citing a local generic injectables market that was worth around $860m, the firm noted that it was “already supporting the...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
